123 related articles for article (PubMed ID: 32949646)
1. Co-delivery of homoharringtonine and doxorubicin boosts therapeutic efficacy of refractory acute myeloid leukemia.
Yan D; Wei H; Lai X; Ge Y; Xu S; Meng J; Wen T; Liu J; Zhang W; Wang J; Xu H
J Control Release; 2020 Nov; 327():766-778. PubMed ID: 32949646
[TBL] [Abstract][Full Text] [Related]
2. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
Wang F; Xie M; Chen P; Wang D; Yang M
Oxid Med Cell Longev; 2022; 2022():8212286. PubMed ID: 35873796
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
5. Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia.
Liu Q; Luo L; Gao X; Zhang D; Feng X; Yang P; Li H; Mao S
J Pharm Sci; 2023 Jan; 112(1):123-131. PubMed ID: 35469834
[TBL] [Abstract][Full Text] [Related]
6. Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia.
Zhang M; Ge Y; Xu S; Fang X; Meng J; Yu L; Wang C; Liu J; Wen T; Yang Y; Wang C; Xu H
Pharmacol Res; 2022 Nov; 185():106503. PubMed ID: 36241000
[TBL] [Abstract][Full Text] [Related]
7. [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Ma XR; Wang J; Zhang WG; Chen YX; Cao XM; He AL; Liu J; Wang JL; Gu LF; Lei B; Zhang PY; Zhao WH; Yang Y; Wang FX; Xu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):369-74. PubMed ID: 25948187
[TBL] [Abstract][Full Text] [Related]
8. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
10. Hydrophilic Realgar Nanocrystals Prolong the Survival of Refractory Acute Myeloid Leukemia Mice Through Inducing Multi-Lineage Differentiation and Apoptosis.
Wang T; Zhang X; Jia M; Yang A; Liu J; Wen T; Meng J; Xu H
Int J Nanomedicine; 2022; 17():2191-2202. PubMed ID: 35599749
[TBL] [Abstract][Full Text] [Related]
11. Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia.
Meng J; Ge Y; Xing H; Wei H; Xu S; Liu J; Yan D; Wen T; Wang M; Fang X; Ma L; Yang Y; Wang C; Wang J; Xu H
Small; 2020 Aug; 16(31):e2001890. PubMed ID: 32608185
[TBL] [Abstract][Full Text] [Related]
12. FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.
Quarello P; Berger M; Rivetti E; Galletto C; Masetti R; Manicone R; Barisone E; Pession A; Fagioli F
J Pediatr Hematol Oncol; 2012 Apr; 34(3):208-16. PubMed ID: 22395219
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
14. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
[TBL] [Abstract][Full Text] [Related]
15. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
16. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Fan C; Yu W; Mai W; Meng H; Qian W; Tong H; Huang J; Mao L; Suo S; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):100-4. PubMed ID: 27014977
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Jing Y; Zhu CY; Zhang Q; Niu JH; Yang H; Liu SY; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1245-50. PubMed ID: 25338566
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.
Chen X; Tang Y; Chen J; Chen R; Gu L; Xue H; Pan C; Tang J; Shen S
Front Med; 2019 Jun; 13(3):378-387. PubMed ID: 30635781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
